# Remission of Graves’ Disease Through Lifestyle Interventions

**Authors:** Pranjali Sharma

PMC · DOI: 10.7759/cureus.81900 · 2025-04-08

## TL;DR

A 39-year-old woman with Graves' disease achieved remission through lifestyle changes like diet, exercise, and stress management, without using anti-thyroid drugs.

## Contribution

This case demonstrates that non-pharmacological lifestyle interventions can lead to clinical and biochemical remission in Graves' disease.

## Key findings

- The patient's thyroid hormone levels and antibodies normalized over three months with lifestyle changes.
- Lifestyle interventions included a dairy- and gluten-free diet, Brazil nuts, exercise, mindfulness, and cold-water immersion.
- The patient avoided anti-thyroid drugs and achieved remission through alternative measures.

## Abstract

Graves' disease, caused by autoimmune thyrotropin receptor antibody-mediated activation of the thyroid, is characterized by hyperthyroidism, orbitopathy, dermopathy, and acropachy. Graves' disease is treated by anti-thyroid drug therapy, radioactive iodine ablation, or total thyroidectomy. We report the case of a 39-year-old female patient with hyperthyroidism secondary to Graves' disease that was managed through lifestyle interventions only. On presentation, she reported intermittent headaches and had an undetectable thyroid-stimulating hormone (TSH) level. Two weeks later, repeat testing showed an undetectable TSH, free thyroxine (free T4) 2.7 ng/dL (normal range: 0.70-1.48 ng/dL), total triiodothyronine (T3) 5.08 ng/mL (normal range: 0.40-1.93 ng/mL), thyrotropin receptor antibody (TRAb) 20.3 IU/L (reference range: ≤1.75 IU/L), thyroid stimulating immunoglobulin (TSI) 2.3 IU/L (reference range: ≤0.54 IU/L), thyroid peroxidase antibody (TPO) 7.66 IU/mL (reference range: <5.61 IU/mL), confirming hyperthyroidism due to Graves' disease. An iodine-123 (I-123) thyroid uptake and scan showed homogeneously increased iodine uptake (68%) at 4 hours (normal range: 3-16%) and (60%) 24 hours (normal range: 8-25%). The patient was prescribed anti-thyroid drug therapy through methimazole but elected not to take it due to concerns about side effects. She incorporated lifestyle interventions and, over a span of three months, was able to improve clinically and biochemically (TSH: 0.824 mcIU/mL, free T4: 0.77 ng/dL, total T3: 0.73 ng/mL, TRAb: 2.93 IU/L, TSI: 0.26 IU/L, and TPO antibody: undetectable). The lifestyle interventions she pursued included going dairy and gluten-free, ingestion of one to two Brazil nuts daily, regular exercise, mindfulness-based stress management, and cold-water immersion therapy. We review the evidence behind these interventions and discuss the utility of these measures in the management of Graves' disease.

## Linked entities

- **Chemicals:** methimazole (PubChem CID 1349907)
- **Diseases:** Graves' disease (MONDO:0005364), hyperthyroidism (MONDO:0004425)

## Full-text entities

- **Genes:** TSHR (thyroid stimulating hormone receptor) [NCBI Gene 7253] {aka CHNG1, LGR3, hTSHR-I}, TPO (thyroid peroxidase) [NCBI Gene 7173] {aka MSA, TDH2A, TPX}
- **Diseases:** headaches (MESH:D006261), orbitopathy (MESH:D049970), hyperthyroidism (MESH:D006980), acropachy (MESH:D010004), dermopathy (MESH:C536920), Graves' Disease (MESH:D006111)
- **Chemicals:** T4 (MESH:D013974), iodine (MESH:D007455), T3 (MESH:D014284), radioactive iodine (-), methimazole (MESH:D008713), I-123 (MESH:C000614958)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11978162/full.md

---
Source: https://tomesphere.com/paper/PMC11978162